AiViva BioPharma, Inc. is a privately held clinical-stage biotech company that is developing revolutionary technologies to meet unmet medical needs by converting current medicines to generate localized, targeted disease treatment while reducing systemic exposure. Their expertise includes the creation of pharmaceuticals in the specialty therapeutic areas of dermatology, ophthalmology, urology, and oncology utilizing their unique JELTM Technology. They are developing formulations, oncology, dermatology, ophthalmology, clinical, and delivery formulations.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.

Allgenesis Biotherapeutics, Inc. is a private company headquartered in Taipei, Taiwan. The firm develops biopharmaceutical products. It was founded by Chih Ming Chen and Chih Lung Shen. Madhu Cherukury is the CEO, in this role since 2014.\nThe company says this about itself: Allgenesis is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, nAMD, and other retinal diseases such as RVO, AG-86893 for pterygium, and AG-80308 for Dry Eye Disease.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a company headquartered in Allschwil, Switzerland. The firm develops and commercializes pharmaceuticals. Jean-Paul Clozel is the current CEO, occupying that position since 2017.\nThe company says this about itself: Headquartered near Basel, Switzerland - a biotech-hub of Europe-Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of over 700 highly qualified specialists dedicated to realizing our ambitious targets, a fully functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Shanghai Kesheng Pharmaceutical Research and Development Co., Ltd., established on 2005-04-08, Business scope includes biological,Research and development of pharmaceutical products and technology transfer,Sales of pharmaceutical intermediates,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Ruiyang (Suzhou) Biotechnology Co., Ltd., established on 2015-04-08, Business scope includes research and development of small molecule protein drugs,And provide technical advice,Technology Transfer and Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zentiva ks specializes in the development, manufacture and marketing of generic pharmaceutical products. It offers generic drugs, over the counter medicines, dietary supplements, cosmetics and pharmaceutical substances. The company's products cover therapy areas of cardiovascular disease, pain, alimentary, genitourinary tract diseases, inflammations and central nervous system diseases including digestive problems. Zentiva was founded in 1989 and is headquartered in Prague, Czech Republic.

PAEAN Biotechnology, Inc. is a company headquartered in Daejeon, the South Korea, that provides biotechnology research and development services. It was founded in 2013 by Gyu-Beom Han, who has been the CEO since the inception date.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Fermion develops, manufactures, and markets active pharmaceutical ingredients (APIs) for companies in the global generic market as well as under exclusive contracts to companies focusing on new chemical entities (NCEs). Their API product portfolio consists of over 30 generic APIs and over 10 NCEs. Fermion’s two state-of-the-art manufacturing sites as well as R&D facilities, including a modern bench scale operation, are all located in Finland. Fermion has systematically invested and expanded capabilities in the production of highly potent compounds (HPAPIs).

Qx Therapeutics Inc. is a drug research and development company aiming to provide innovative treatment toward unmet medical needs in the acute lung injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) disease area.

Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for Generic as well as for contract manufacturing. OLON owns 5 manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees while INFA Group, with more than 400 employees, has 2 manufacturing sites in Italy, Labochim and Sifavitor, and 1 in Spain, Derivados Químicos.

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. It also integrates and intermediates formulations such as Active Pharmaceutical Ingredients. Its products include Irbesartan and Hydrochlorothiazide Tablet, Paroxetine Hydrochloride Tablet and Irbesartan Tablet. The company was founded in 1989 and is headquartered in Zhejiang, China.

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research and development, manufacture, distribution, and retail of pharmaceutical products. The company was founded on January 18, 1994 and is headquartered in Shanghai, China.

Shenzhen Taili Biomedical Co., Ltd., established on 2018-05-02, Business scope includes general business items:Research and development of new biomedical technologies,transfer,Serve.,The licensing program is:chemical preparation,Biopharmaceuticals,Chinese patent medicine preparation,Healthy food,Research and development of sanitary materials and medical supplies,Production,Sales.Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Cloud Dispelling Biomedical Technology (Guangzhou) Co., Ltd., established on 2018-09-30, Business scope includes drug research and development(human stem cells,Except for genetic diagnosis and treatment technology);Pharmaceutical Research Services;Technology Import and Export;Medical Research and Experimental Development(human stem cells,Except for genetic diagnosis and treatment technology)